Exelixis Inc Research and Development in Process
Exelixis Inc (EXEL) reported Research and Development in Process of $36.50 million for the 3-month period ending 2023-03-31, per its 10-Q filed 2023-05-09.
Discontinued › Expense Statement › Operating Expenses
us-gaap:ResearchAndDevelopmentInProcess · last filed 2023-05-09
- Exelixis Inc research and development in process for the quarter ending 2023-03-31 was $36.50M.
- Exelixis Inc research and development in process for the quarter ending 2022-04-01 was $0.00.
- Exelixis Inc research and development in process for fiscal 2022 was $107.25M, a 666.07% increase from fiscal 2021.
- Exelixis Inc research and development in process for fiscal 2021 was $14.00M.
- Exelixis Inc research and development in process for fiscal 2021 was $0.00.
| Period end | Research and Development in Process 3 month | Research and Development in Process 12 month |
|---|---|---|
| 2023-03-31 | $36.50M 10-Q · filed 2023-05-09 | |
| 2022-12-30 | $107.25M 10-K · filed 2023-02-07 | |
| 2022-04-01 | $0.00 10-Q · filed 2023-05-09 | |
| 2021-12-31 | $14.00M 10-K · filed 2023-02-07 | |
| 2021-01-01 | $0.00 10-K · filed 2023-02-07 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| NEUROCRINE BIOSCIENCES INC (NBIX) | United States | $14.131B | 24.25 |
| HALOZYME THERAPEUTICS, INC. (HALO) | United States | $13.083B | 21.59 |
| Twist Bioscience Corp (TWST) | United States | $11.540B | -47.21 |
| BIO-TECHNE Corp (TECH) | United States | $11.379B | 74.68 |
| REPLIGEN CORP (RGEN) | United States | $10.755B | 185.31 |
| Krystal Biotech, Inc. (KRYS) | United States | $10.210B | 45.56 |
| Kymera Therapeutics, Inc. (KYMR) | United States | $9.631B | -31.69 |
| ImmunityBio, Inc. (IBRX) | United States | $9.157B | -9.29 |
| Vaxcyte, Inc. (PCVX) | United States | $8.466B | -7.91 |
| Immunovant, Inc. (IMVT) | United States | $7.028B | -14.78 |